Sagimet Biosciences (NasdaqGM:SGMT) FY Conference Transcript

Summary of Sagimet Biosciences FY Conference Call Company Overview - Company: Sagimet Biosciences (NasdaqGM:SGMT) - Focus: Development of treatments for metabolic diseases, specifically targeting NASH (Non-Alcoholic Steatohepatitis) and acne Key Points Industry and Product Development - NASH Treatment: Sagimet is focusing on combination therapies for NASH, particularly using denifanstat, a FASN inhibitor, as a foundational treatment strategy [10][12] - Combination Approach: The company is exploring the combination of denifanstat with resmetirom, which has shown promising preclinical data indicating a synergistic effect in reducing inflammation and fibrosis [10][13][25] - Clinical Data: In patients with F4 stage disease, 11 out of 13 showed improvement in disease severity, indicating the effectiveness of denifanstat [12][13] Strategic Licensing and Development - API License: Sagimet has obtained a license for 20 novel forms of the resmetirom API from Teva, with no anticipated pharmacodynamic differences from the approved form [29][31] - Selection Process: The company is in the process of selecting the most effective version of resmetirom based on pharmacokinetics (PK), pharmacodynamics (PD), and solubility [40][41] Clinical Trials and Safety - Phase 1 Study: Completed with no safety signals reported, indicating compatibility and tolerability of the combination therapy [51][53] - Phase 2 Plans: The company plans to submit data from the Phase 1 study to EASL and is preparing for Phase 2 trials, which will not require new safety data for the new polymorph [57][127][128] Acne Treatment Development - Market Size: Approximately 50 million Americans suffer from acne, with 10 million having moderate to severe cases [184] - Innovative Mechanism: Sagimet's acne treatment aims to reduce sebum production, which is a novel approach compared to existing treatments [199][200] - Phase 1 Study for Acne: Initiated in June 2025, with expected readouts by the end of the year to inform Phase 2 program [205][206] Financial Outlook - Cash Position: As of the end of Q3, Sagimet reported $125 million, providing approximately two years of runway to support both MASH and acne programs [386] - Milestone Payments: Potential milestones from the Asian partner, Ascletis, could exceed $122 million, primarily based on commercial performance [378][380] Regulatory Considerations - FDA Meetings: The next critical step involves discussions with the FDA regarding the Phase 2 trial for MASH, expected in the first half of the year [156][160] - Approval Timeline: Anticipated approval from the NMPA for the Asian partner's product could occur within 10-16 months following NDA acceptance [376][377] Conclusion - Dual Focus: Sagimet is strategically prioritizing both MASH and acne treatment developments, leveraging its financial resources to advance both programs effectively [386][388]